LISATA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.913 USD | +5.93% |
|
-0.58% | +6.70% |
Presentation Operator MessageOperator (Operator)Welcome to the Caladrius Biosciences' Second Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
Calendar
04:05pm
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.75
USD
Average target price
14.5
USD
Spread / Average Target
+427.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.70% | 22.85M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- LSTA Stock
- News Lisata Therapeutics, Inc.
- Transcript : Caladrius Biosciences, Inc., Q2 2022 Earnings Call, Aug 04, 2022